![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1313815 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of PPP2R5E mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | affects expression | ISO | RGD:1313815 | 6480464 | Ethinyl Estradiol affects the expression of PPP2R5E mRNA | CTD | PMID:17555576 | 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:1313815 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PPP2R5E mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | increases expression | ISO | RGD:1313815 | 6480464 | Ethinyl Estradiol results in increased expression of PPP2R5E mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | decreases expression | ISO | RGD:1313815 | 6480464 | Ethinyl Estradiol results in decreased expression of PPP2R5E mRNA | CTD | PMID:17942748 | 2,2',4,4'-Tetrabromodiphenyl ether | increases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:27291303 | 2,2',4,4'-Tetrabromodiphenyl ether | decreases expression | ISO | RGD:1313814 | 6480464 | 2 more ... | CTD | PMID:31675489 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1313815 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PPP2R5E mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1313815 | 6480464 | Tetrachlorodibenzodioxin affects the expression of PPP2R5E mRNA | CTD | PMID:21570461, PMID:24680724 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1313815 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PPP2R5E mRNA | CTD | PMID:23994337 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PPP2R5E mRNA | CTD | PMID:21215274 | 2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 2, 6-dinitrotoluene affects the expression of PPP2R5E mRNA | CTD | PMID:21346803 | 3,3',4,4',5-pentachlorobiphenyl | decreases expression | ISO | RGD:1313815 | 6480464 | 3 more ... | CTD | PMID:23994337 | 3,3',4,4'-tetrachlorobiphenyl | multiple interactions | ISO | RGD:1313815 | 6480464 | 3 more ... | CTD | PMID:19467301 | 3,3',5,5'-tetrabromobisphenol A | decreases expression | ISO | RGD:1313814 | 6480464 | tetrabromobisphenol A results in decreased expression of PPP2R5E protein | CTD | PMID:31675489 | Aflatoxin B2 alpha | decreases methylation | ISO | RGD:1313814 | 6480464 | aflatoxin B2 results in decreased methylation of PPP2R5E intron | CTD | PMID:30157460 | antirheumatic drug | increases expression | ISO | RGD:1313814 | 6480464 | Antirheumatic Agents results in increased expression of PPP2R5E mRNA | CTD | PMID:24449571 | aristolochic acid | decreases expression | ISO | RGD:1313814 | 6480464 | aristolochic acid I results in decreased expression of PPP2R5E mRNA | CTD | PMID:33212167 | arsenite(3-) | multiple interactions | ISO | RGD:1313814 | 6480464 | arsenite promotes the reaction [G3BP1 protein binds to PPP2R5E mRNA] | CTD | PMID:32406909 | atrazine | decreases expression | ISO | RGD:1313814 | 6480464 | Atrazine results in decreased expression of PPP2R5E mRNA | CTD | PMID:22378314 | benzo[a]pyrene | decreases expression | ISO | RGD:1313815 | 6480464 | Benzo(a)pyrene results in decreased expression of PPP2R5E mRNA | CTD | PMID:19770486 | benzo[a]pyrene | affects methylation | ISO | RGD:1313814 | 6480464 | Benzo(a)pyrene affects the methylation of PPP2R5E intron | CTD | PMID:30157460 | benzo[a]pyrene | increases expression | ISO | RGD:1313815 | 6480464 | Benzo(a)pyrene results in increased expression of PPP2R5E mRNA | CTD | PMID:22228805 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1313814 | 6480464 | 7 more ... | CTD | PMID:19150397, PMID:20018196 | benzo[e]pyrene | decreases methylation | ISO | RGD:1313814 | 6480464 | benzo(e)pyrene results in decreased methylation of PPP2R5E intron | CTD | PMID:30157460 | beta-naphthoflavone | increases expression | ISO | RGD:1313815 | 6480464 | beta-Naphthoflavone results in increased expression of PPP2R5E mRNA | CTD | PMID:23994337 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of PPP2R5E mRNA | CTD | PMID:25181051 | bisphenol A | decreases methylation | ISO | RGD:1313814 | 6480464 | bisphenol A results in decreased methylation of PPP2R5E gene | CTD | PMID:31601247 | bisphenol A | decreases expression | ISO | RGD:1313814 | 6480464 | bisphenol A results in decreased expression of PPP2R5E protein | CTD | PMID:31675489 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of PPP2R5E gene | CTD | PMID:28505145 | camptothecin | multiple interactions | ISO | RGD:1313814 | 6480464 | Camptothecin affects the localization of [PPP2R5E protein binds to PPP2CA protein], PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form] | CTD | PMID:25772433 | camptothecin | decreases response to substance | ISO | RGD:1313814 | 6480464 | PPP2R5E protein results in decreased susceptibility to Camptothecin | CTD | PMID:25772433 | carbon nanotube | increases expression | ISO | RGD:1313815 | 6480464 | Nanotubes, Carbon results in increased expression of PPP2R5E mRNA | CTD | PMID:25620056 | choline | multiple interactions | ISO | RGD:1313815 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of PPP2R5E mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of PPP2R5E gene | CTD | PMID:20938992 | ciguatoxin CTX1B | affects expression | ISO | RGD:1313815 | 6480464 | Ciguatoxins affects the expression of PPP2R5E mRNA | CTD | PMID:18353800 | copper(II) sulfate | increases expression | ISO | RGD:1313814 | 6480464 | Copper Sulfate results in increased expression of PPP2R5E mRNA | CTD | PMID:19549813 | coumestrol | decreases expression | ISO | RGD:1313814 | 6480464 | Coumestrol results in decreased expression of PPP2R5E mRNA | CTD | PMID:19167446 | cyclosporin A | decreases expression | ISO | RGD:1313815 | 6480464 | Cyclosporine results in decreased expression of PPP2R5E mRNA | CTD | PMID:19770486 | decabromodiphenyl ether | increases expression | EXP | | 6480464 | decabromobiphenyl ether results in increased expression of PPP2R5E mRNA | CTD | PMID:23640034 | disodium selenite | increases expression | ISO | RGD:1313814 | 6480464 | Sodium Selenite results in increased expression of PPP2R5E mRNA | CTD | PMID:18175754 | dorsomorphin | multiple interactions | ISO | RGD:1313814 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1313814 | 6480464 | Doxorubicin results in decreased expression of PPP2R5E mRNA | CTD | PMID:29803840 | Echimidine | multiple interactions | ISO | RGD:1313814 | 6480464 | [CYP3A4 protein results in increased metabolism of echimidine] which results in increased expression of PPP2R5E mRNA | CTD | PMID:33884520 | elemental selenium | decreases expression | ISO | RGD:1313814 | 6480464 | Selenium results in decreased expression of PPP2R5E mRNA | CTD | PMID:19244175 | folic acid | multiple interactions | ISO | RGD:1313815 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of PPP2R5E mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of PPP2R5E gene | CTD | PMID:20938992 | formaldehyde | decreases expression | ISO | RGD:1313814 | 6480464 | Formaldehyde results in decreased expression of PPP2R5E mRNA | CTD | PMID:23649840 | glafenine | decreases expression | EXP | | 6480464 | Glafenine results in decreased expression of PPP2R5E mRNA | CTD | PMID:24136188 | gold atom | multiple interactions | ISO | RGD:1313815 | 6480464 | [Gold co-treated with Polyethylene Glycols] results in decreased expression of PPP2R5E mRNA | CTD | PMID:19695318 | gold(0) | multiple interactions | ISO | RGD:1313815 | 6480464 | [Gold co-treated with Polyethylene Glycols] results in decreased expression of PPP2R5E mRNA | CTD | PMID:19695318 | ivermectin | decreases expression | ISO | RGD:1313814 | 6480464 | Ivermectin results in decreased expression of PPP2R5E protein | CTD | PMID:32959892 | L-methionine | multiple interactions | ISO | RGD:1313815 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of PPP2R5E mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of PPP2R5E gene | CTD | PMID:20938992 | methapyrilene | decreases methylation | ISO | RGD:1313814 | 6480464 | Methapyrilene results in decreased methylation of PPP2R5E intron | CTD | PMID:30157460 | methapyrilene | decreases expression | EXP | | 6480464 | Methapyrilene results in decreased expression of PPP2R5E mRNA | CTD | PMID:30467583 | mitomycin C | decreases response to substance | ISO | RGD:1313814 | 6480464 | PPP2R5E protein results in decreased susceptibility to Mitomycin | CTD | PMID:25772433 | monocrotaline | multiple interactions | ISO | RGD:1313814 | 6480464 | [CYP3A4 protein results in increased metabolism of Monocrotaline] which results in increased expression of PPP2R5E mRNA | CTD | PMID:33884520 | N-methyl-N'-nitro-N-nitrosoguanidine | decreases response to substance | ISO | RGD:1313814 | 6480464 | PPP2R5E protein results in decreased susceptibility to Methylnitronitrosoguanidine | CTD | PMID:25772433 | nefazodone | decreases expression | EXP | | 6480464 | nefazodone results in decreased expression of PPP2R5E mRNA | CTD | PMID:24136188 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of PPP2R5E mRNA | CTD | PMID:25729387 | paracetamol | decreases expression | ISO | RGD:1313814 | 6480464 | Acetaminophen results in decreased expression of PPP2R5E mRNA | CTD | PMID:21420995 | pentachlorophenol | affects expression | ISO | RGD:1313815 | 6480464 | Pentachlorophenol affects the expression of PPP2R5E mRNA | CTD | PMID:23892564 | phenobarbital | decreases expression | ISO | RGD:1313815 | 6480464 | Phenobarbital results in decreased expression of PPP2R5E mRNA | CTD | PMID:23091169 | phenylmercury acetate | decreases expression | ISO | RGD:1313814 | 6480464 | Phenylmercuric Acetate results in decreased expression of PPP2R5E mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1313814 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R5E mRNA | CTD | PMID:27188386 | pirinixic acid | decreases expression | ISO | RGD:1313815 | 6480464 | pirinixic acid results in decreased expression of PPP2R5E mRNA | CTD | PMID:23811191 | SB 431542 | multiple interactions | ISO | RGD:1313814 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | selenium atom | decreases expression | ISO | RGD:1313814 | 6480464 | Selenium results in decreased expression of PPP2R5E mRNA | CTD | PMID:19244175 | tamoxifen | affects expression | ISO | RGD:1313815 | 6480464 | Tamoxifen affects the expression of PPP2R5E mRNA | CTD | PMID:17555576 | taurine | decreases expression | ISO | RGD:1313814 | 6480464 | Taurine results in decreased expression of PPP2R5E mRNA | CTD | PMID:16579726 | toluene | affects expression | EXP | | 6480464 | Toluene affects the expression of PPP2R5E mRNA | CTD | PMID:21827849 | topotecan | decreases expression | EXP | | 6480464 | Topotecan results in decreased expression of PPP2R5E mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of PPP2R5E mRNA | CTD | PMID:25729387 | trichloroethene | increases methylation | EXP | | 6480464 | Trichloroethylene results in increased methylation of PPP2R5E gene | CTD | PMID:27618143 | triptonide | increases expression | ISO | RGD:1313815 | 6480464 | triptonide results in increased expression of PPP2R5E mRNA | CTD | PMID:33045310 | tunicamycin | increases expression | ISO | RGD:1313815 | 6480464 | Tunicamycin results in increased expression of PPP2R5E mRNA | CTD | PMID:17127020 | valdecoxib | decreases expression | EXP | | 6480464 | valdecoxib results in decreased expression of PPP2R5E mRNA | CTD | PMID:24136188 | valproic acid | affects expression | ISO | RGD:1313815 | 6480464 | Valproic Acid affects the expression of PPP2R5E mRNA | CTD | PMID:17292431 | valproic acid | multiple interactions | ISO | RGD:1313814 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R5E mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | RGD:1313814 | 6480464 | Valproic Acid results in decreased expression of PPP2R5E mRNA | CTD | PMID:23179753 more ... | vinclozolin | affects expression | EXP | | 6480464 | vinclozolin affects the expression of PPP2R5E mRNA | CTD | PMID:19015723 | |